Saporin
From Proteopedia
(Difference between revisions)
| (15 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | + | <StructureSection load='1qi7' size='340' side='right' caption='Caption for this structure' scene=''> | |
| - | <StructureSection load=' | + | |
| - | + | ||
| - | + | ||
| - | + | ||
== Function == | == Function == | ||
Saporin is a ribosome-inactivating protein (RIP); alone, saporin does not selectively inactive ribosomes but rather conjugate with other molecules like peptides <ref name="basel">DOI: | Saporin is a ribosome-inactivating protein (RIP); alone, saporin does not selectively inactive ribosomes but rather conjugate with other molecules like peptides <ref name="basel">DOI: | ||
| - | 10.3390/toxins12090546</ref>. Saponaria officinalis is the plant from which saporin is extracted <ref name="ncbi">DOI: 10.3390/toxins5101698</ref>. Type I and type II RIPS exist. Of these types, saporin is a type I. Ribosome inactivating proteins catalyze a cleavages N-glycosidic bond that is formed between the ribosome and adenine <ref name="rcsb">DOI: 10.1016/s0014-5793(00)01325-9</ref>. This adenine has the role of binding EF-1 and EF-2 to a ribosome <ref name="rcsb" />. EF stands for elongation factor. Since adenine no longer has a bond to the ribosome, the elongation step in translation cannot occur because the elongation factors cannot bind to just the ribosome. The specific elongation factor that is inhibited is elongation factor 2, which causes irreversible damage and disallows protein synthesis <ref name="ncbi" />. | + | 10.3390/toxins12090546</ref>. Saponaria officinalis is the plant from which saporin is extracted <ref name="ncbi">DOI: 10.3390/toxins5101698</ref>. Type I and type II RIPS exist. Of these types, saporin is a type I. Ribosome inactivating proteins catalyze a cleavages N-glycosidic bond that is formed between the ribosome and adenine <ref name="rcsb">DOI: 10.1016/s0014-5793(00)01325-9</ref>. This adenine has the role of binding EF-1 and EF-2 to a ribosome <ref name="rcsb" />. EF stands for elongation factor. Since adenine no longer has a bond to the ribosome, the elongation step in translation cannot occur because the elongation factors cannot bind to just the ribosome. The specific elongation factor that is inhibited is elongation factor 2, which causes irreversible damage and disallows protein synthesis <ref name="ncbi" />. |
== Structural highlights == | == Structural highlights == | ||
Type 1 RIPS are monomeric, meaning they have one part <ref name="fab">DOI: 10.3390/toxins9100314</ref>. Saporin-S6 at maturity is 256 amino acids long <ref name="ncbi" />. While saporin consists of different residues and molecules, there is only one Chain A in it, and thus is monomeric. Chain A is a polypeptide weighing 30 KDa <ref name="nano">DOI: 10.3390/cancers12020498</ref>. This chain consists of beta-sheets and alpha-helixes. The β-sheets make up the N-terminal domain, while the 𝛼-helix portion is the C-terminal domain <ref name="rcsb" />. In the figure of Chain A, the 𝛼-helices are spiral-shaped strands, while the β-sheets are more of a flat strand. | Type 1 RIPS are monomeric, meaning they have one part <ref name="fab">DOI: 10.3390/toxins9100314</ref>. Saporin-S6 at maturity is 256 amino acids long <ref name="ncbi" />. While saporin consists of different residues and molecules, there is only one Chain A in it, and thus is monomeric. Chain A is a polypeptide weighing 30 KDa <ref name="nano">DOI: 10.3390/cancers12020498</ref>. This chain consists of beta-sheets and alpha-helixes. The β-sheets make up the N-terminal domain, while the 𝛼-helix portion is the C-terminal domain <ref name="rcsb" />. In the figure of Chain A, the 𝛼-helices are spiral-shaped strands, while the β-sheets are more of a flat strand. | ||
| - | There is an active site within this chain that consists of five residues. These residues are Tyr⁷², Tyr¹²⁰, Glu¹⁷⁶, Arg¹⁷⁹, and Trp²⁰⁸ <ref name="ncbi" />. Other RIPs also have these same residues in their active sites. The saporin active has Glu¹⁷⁶, Arg¹⁷⁹, and Trp²⁰⁸ in the exact same position as the other ribosome-inactivating proteins. There is a difference in Tyr⁷², which has different side-chain conformations in RIPs and thus is not the same in saporin and other RIPs. This Tyr⁷² is the residue that interacts with the adenine in the cleavage of adenine and the ribosome <ref name="rcsb" />. | + | There is an <scene name='91/910029/Active_site/1'>active site</scene> within this chain that consists of five residues. These residues are <scene name='91/910569/Active_site_tyr/1'>Tyr⁷²</scene>, <scene name='91/910029/Active_site_tyr_120/1'>Tyr¹²⁰</scene>, <scene name='91/910029/Active_site_glu_176/1'>Glu¹⁷⁶</scene>, <scene name='91/910029/Active_site_arg_179/3'>Arg¹⁷⁹</scene>, and <scene name='91/910029/Active_site208/2'>Trp²⁰⁸</scene> <ref name="ncbi">DOI: 10.3390/toxins5101698</ref>. Other RIPs also have these same residues in their active sites. The saporin active has Glu¹⁷⁶, Arg¹⁷⁹, and Trp²⁰⁸ in the exact same position as the other ribosome-inactivating proteins. There is a difference in Tyr⁷², which has different side-chain conformations in RIPs and thus is not the same in saporin and other RIPs. This Tyr⁷² is the residue that interacts with the adenine in the cleavage of adenine and the ribosome <ref name="rcsb" />. |
| + | |||
| + | Saporin can also be complexed with other inhibitors. One of these is cyclic tetranucleotide inhibitor in <scene name='91/910569/Complex_of_saporin_with_tetra/1'>complex with saporin-L1</scene>. This can be used because the cyclic tetranucleotide can take the place of the recognition loop for saporin of 28S rRNA <ref name="pnas">DOI: 0.1073/pnas.0911606106</ref>. It is also interesting to note that Ricin can also be complex with other inhibitors like saporin. Saporin is a homologue of Ricin A-Chain which means they are similar in structure <ref name="pnas" />. This ability also allows for saporin-S6 to be conjugated with specific targeting proteins, and thus the saporin-S6 is able to be delivered to the cell. This happens due to the antibodies and is referred to as an immunotoxin <ref name="ncbi" />. The antibodies are recognized by the cell, and the cell binds them. Since the saporin-S6 is in complex with the antibody, it is also taken to the cell. Some other carries can also be used, such as growth factors, antigens, and growth hormones <ref name="ncbi" />. | ||
| + | |||
| + | ==Medical Uses== | ||
| + | Medical uses for saporin have been studied as well. Most notably, the use of saporin as an anti-tumor agent or anti-cancer agent. Research has been done to determine if and how saporin could be used to treat cancer. Cancer treatments include many things, some of which are tumor debulking surgeries and chemotherapy. Although toxins like saporin can cause cell death, if saporin can be used to target cancer, it would kill off cancer cells. The delivery of drugs to a specific tissue can be used to avoid healthy tissue but harm the diseased tissue or cancer tissue <ref name="par">DOI: 10.1038/s41598-020-59313-8</ref>. Saporin is toxic to cancer cells due to its level of enzymatic activity and saponin’s resistance to conjugation. This toxicity causes apoptosis, cell death to the targeted cancer cells <ref name="nano" />. Assays of saporin-S6’s ability to induce apoptosis and necrosis are also being studied <ref name="ncbi" />. Saporin-S6 has been used in mice to study its effects on tumors and cancers. Mice were injected with saporin-S6 at a dose that was non-lethal to them. They were then left and later examined for tumors throughout their bodies. The best results were in the liver, but then no tumors were reported 14 days after the initial saporin-S6 injection <ref name="ncbi" />. | ||
| + | |||
| + | One way that has been researched to treat cancer with saporin is by using an amino-terminal fragment (ATF) and fusing it with saporin (SAP) <ref name="par" />. The specific ATF used was the human urokinase-type plasminogen activator (uPA) which is the ligand to the urokinase plasminogen activator receptor (uPAR). This means that uPAR will bind uPA, and if saporin is fused with uPA, it will also be bound to the uPAR. This is important because uPAR is upregulated, increasing its levels in cancer cells <ref name="par" />. With increased levels, it means that more uPA will be in the cancer cell and again more saporin since the saporin is bounded to the uPA. This particular study found that the ATF-SAP was able to get into the cancer cells and kill the cells in cancer cells. Although, with lower and undetectable levels of uPAR, there was no effect on cancer with ATF-SAP <ref name="par" />. Saporin can be bound to other molecules to make it effective for specific things in the body. Although, there need to be appropriate levels of what is being targeted, or the saporin won't be able to get to where it needs to be to achieve the goal. | ||
| + | |||
| + | The study explained above has saporin being used as a chimeric toxin, which is different from that of an immunotoxin <ref name="ncbi" />. This just means that the saporin is conjugated with another carrier rather than one, such as antibodies <ref name="ncbi" />. One way that this is helpful is so that the saporin does not activate an immune response. In general, plant toxin-based chimerae have shown less immune response when compared to bacterial origin toxins <ref name="fab" />. Since there is less immune response, the body will not attack the saporin conjugates, at least not as much, and the saporin can get to the target area, most likely cancer. | ||
| + | |||
| + | It is apparent through different studies that the delivery method of saporin is essential. Overall, saporin does not penetrate cancer cells that well. As seen previously, saporin can be bound to another molecule to achieve this. Some mechanisms have been thought of for how saporin enters the cell. Some of which are passive mechanisms, although due to cells in the body showing resistance to saporin-S6, the idea of a receptor for saporin <ref name="ncbi" />. | ||
| + | |||
| + | Another study used a lipid-based nanoparticle and loaded saporin into it <ref name="nano" />. These nanoparticles can serve as a sort of delivery system to the target cells. The problem trying to be solved in this particular study was getting around multidrug resistance (MDR), which happens when cancer is resistant to many unrelated drugs. One reason that cancer cells become resistant is due to the ATP-binding cassette (ABC) transporters that are overexpressed in the cancer cells <ref name="nano" />. The use of saporin in the nanoparticle was to inhibit the ABC transporters. Not only did the study find that saporin successfully accomplished this, but it inhibited the growth of tumors in mice <ref name="nano" />. | ||
| + | |||
| + | There are other uses than just cancer treatment for saporin being studied as well. One of which is the ability for saporin to have some antimicrobial activity. This activity is the same that occurs from pokeweed antiviral protein (PAP) <ref name="fab" />. Substance P-saporin (SP-SAP) is being studied to target a specific neuron that expresses the substance P pain-related receptor <ref name="fab" />. This could help with the pain that terminal cancer patients may experience <ref name="fab" />. While this still connects with cancer, it is for pain management rather than treatment of cancer itself. Other RIPs like saporin are also being studied for these same effects, and since other RIPs are similar in structure to saporin, it is easier to study them when comparing them to saporin. | ||
| - | + | The use of saporin-S6 and other RIPs are still being studied, and their structures are as well. Including what saporin-S6 can be complexed with and what the end result would be. As of right now, there is a promise that saporin-S6 could be used to treat cancers in humans at some point in the future. Hurdles needed to be overcome, like the delivery system, but there could come a day. Also, while saporin-S6 is toxic to cells and could cause damage when targeting cancer cells, it might be more limited than the damage produced by chemotherapy or other cancer treatments. Through research, there could also be more uses for saporin than just cancer treatment as well. | |
| - | This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Current revision
| |||||||||||
References
- ↑ Bolshakov AP, Stepanichev MY, Dobryakova YV, Spivak YS, Markevich VA. Saporin from Saponaria officinalis as a Tool for Experimental Research, Modeling, and Therapy in Neuroscience. Toxins (Basel). 2020 Aug 25;12(9). pii: toxins12090546. doi:, 10.3390/toxins12090546. PMID:32854372 doi:http://dx.doi.org/10.3390/toxins12090546
- ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 Polito L, Bortolotti M, Mercatelli D, Battelli MG, Bolognesi A. Saporin-S6: a useful tool in cancer therapy. Toxins (Basel). 2013 Oct 7;5(10):1698-722. doi: 10.3390/toxins5101698. PMID:24105401 doi:http://dx.doi.org/10.3390/toxins5101698
- ↑ 3.0 3.1 3.2 3.3 doi: https://dx.doi.org/10.1016/s0014-5793(00)01325-9
- ↑ 4.0 4.1 4.2 4.3 4.4 Fabbrini MS, Katayama M, Nakase I, Vago R. Plant Ribosome-Inactivating Proteins: Progesses, Challenges and Biotechnological Applications (and a Few Digressions). Toxins (Basel). 2017 Oct 12;9(10). pii: toxins9100314. doi:, 10.3390/toxins9100314. PMID:29023422 doi:http://dx.doi.org/10.3390/toxins9100314
- ↑ 5.0 5.1 5.2 5.3 5.4 Zhang GN, Gupta P, Wang M, Barbuti AM, Ashby CR Jr, Zhang YK, Zeng L, Xu Q, Fan YF, Chen ZS. Lipid-Saporin Nanoparticles for the Intracellular Delivery of Cytotoxic Protein to Overcome ABC Transporter-Mediated Multidrug Resistance In Vitro and In Vivo. Cancers (Basel). 2020 Feb 21;12(2). pii: cancers12020498. doi:, 10.3390/cancers12020498. PMID:32098067 doi:http://dx.doi.org/10.3390/cancers12020498
- ↑ 6.0 6.1 doi: https://dx.doi.org/0.1073/pnas.0911606106
- ↑ 7.0 7.1 7.2 7.3 Zuppone S, Assalini C, Minici C, Bertagnoli S, Branduardi P, Degano M, Fabbrini MS, Montorsi F, Salonia A, Vago R. The anti-tumoral potential of the saporin-based uPAR-targeting chimera ATF-SAP. Sci Rep. 2020 Feb 13;10(1):2521. doi: 10.1038/s41598-020-59313-8. PMID:32054892 doi:http://dx.doi.org/10.1038/s41598-020-59313-8
